Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Hubei, PR China.
Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China.
BMC Cancer. 2022 Jul 23;22(1):812. doi: 10.1186/s12885-022-09867-9.
Despite the understanding of the COP9 signalosome subunit 5 (CSN5) in tumor genesis, there is no conclusive evidence on its value to predict the survival and prognosis of digestive system tumor patients. Hence this study aimed to evaluate the impact of CSN5 levels on the survival and clinicopathological parameters of digestive system neoplasm patients.
First, a comprehensive search was conducted in four databases. We utilized the Hazard Ratio (HR) with a 95% confidence interval (CI) to evaluate the prognostic value of CSN5 for the overall survival (OS) and recurrence-free survival (RFS) of patients. Then, we estimated the connection between CSN5 and the clinicopathological parameters based on the Odds Ratio (OR) with the corresponding 95% CI.
This meta-analysis included 22 studies and 2193 patients diagnosed with digestive system tumors. High expression of CSN5 was correlated to poorer OS (HR = 2.28, 95% CI: 1.71-3.03; p < 0.00001). Additionally, high CSN5 levels were correlated with worse invasion depth (OR = 0.49, 95% CI: 0.25-0.96, p = 0.04), positive lymphatic metastasis (OR = 0.28, 95% CI: 0.16-0.47, p = 0.00001), positive distant metastasis (OR = 0.32, 95% CI: 0.13-0.76, p = 0.01) and poorer differentiation degree (OR = 0.34, 95% CI: 0.19-0.60, p = 0.0003). However, we did not detect a correlation between CSN5 expression and age, gender, tumor stage, tumor size or vascular invasion. Furthermore, no significant publication bias was detected.
This meta-analysis demonstrated that the overexpression of CSN5 level might foresee poorer OS in digestive system cancer patients. Additionally, CSN5 levels might be related to the prognosis of digestive system tumors.
尽管 COP9 信号体亚基 5（CSN5）在肿瘤发生中的作用已被理解，但尚无确凿证据表明其对预测消化系统肿瘤患者的生存和预后具有价值。因此，本研究旨在评估 CSN5 水平对消化系统肿瘤患者生存和临床病理参数的影响。
首先，在四个数据库中进行了全面搜索。我们使用风险比（HR）及其 95%置信区间（CI）来评估 CSN5 对患者总生存期（OS）和无复发生存期（RFS）的预后价值。然后，我们根据 95%CI 计算的优势比（OR）来估计 CSN5 与临床病理参数之间的关系。
本荟萃分析纳入了 22 项研究和 2193 例诊断为消化系统肿瘤的患者。CSN5 高表达与 OS 较差相关（HR=2.28，95%CI：1.71-3.03；p<0.00001）。此外，CSN5 高水平与侵袭深度更深（OR=0.49，95%CI：0.25-0.96，p=0.04）、阳性淋巴转移（OR=0.28，95%CI：0.16-0.47，p=0.00001）、阳性远处转移（OR=0.32，95%CI：0.13-0.76，p=0.01）和分化程度较差（OR=0.34，95%CI：0.19-0.60，p=0.0003）相关。然而，我们没有发现 CSN5 表达与年龄、性别、肿瘤分期、肿瘤大小或血管侵犯之间的相关性。此外，未检测到明显的发表偏倚。
本荟萃分析表明，CSN5 水平的过表达可能预示着消化系统癌症患者的 OS 较差。此外，CSN5 水平可能与消化系统肿瘤的预后有关。
